You are here: Industry Insights > CLL

News List

Overall, Night Shift Work Not Tied to Higher Lymphoma Risk drugs.com
January 24, 2022
Night shift work may increase the risk for chronic lymphocytic leukemia (CLL), according to a study published online...
Gilead withdraws use of Zydelig to treat cancer ExpressPharma
January 17, 2022
The US FDA gave the drug an accelerated approval to treat relapsed follicular B-cell non-Hodgkin lymphoma and relapsed small lymphocytic leukemia along with relapsed Chronic Lymphocytic Leukemia (CLL).
Imbruvica/Venclyxto tops Gazyva plus chemo in first-line CLL/SLL pharmatimes
June 17, 2021
Johnson & Johnson’s BTK inhibitor Imbruvica plus AbbVie and Roche’s Vencylxto demonstrated superiority over Gazyva plus chemotherapy in a new Phase III study.
Chemotherapy-free combination shows potential in lymphocytic leukaemia trial europeanpharmaceuticalreview
June 09, 2021
Imbruvica® (ibrutinib) plus Venclexta®/Venclyxto® (venetoclax) resulted in 95 percent of chronic lymphocytic leukaemia patients surviving without disease progression for two years.
TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab in Combination with Ukoniq (umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia and Smal drugs
May 26, 2021
TGTX today announced that FDA has accepted the Biologics License Application (BLA) for ublituximab as a treatment for patients with chronic lymphocytic leukemia (CLL) and SLL.
New oral chronic lymphocytic leukaemia treatment made available on NHS europeanpharmaceuticalreview
March 22, 2021
AstraZeneca’s Calquence (acalabrutinib), a chemotherapy-free monotherapy, will be offered to patients with chronic lymphocytic leukaemia.
NICE backs AstraZeneca’s Calquence for CLL pharmatimes
March 18, 2021
The UK National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s Calquence for use on the NHS to treat a common form of leukaemia.
Catapult Receives FDA Clearance of IND for Humanized Anti-CCR7 Antibody americanpharmaceuticalreview
February 22, 2021
Catapult Therapeutics has announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for its lead product candidate CAP-100, an innovative first-in-class humanized anti-CCR7 antibody for treatment ...
Calquence tops Imbruvica in chronic lymphocytic leukaemia study pharmatimes
January 26, 2021
AstraZeneca’s Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) hit the primary endpoint in a Phase III study in chronic lymphocytic leukaemia (CLL).
Two medicines accepted for use by NHS Scotland pharmatimes
December 09, 2020
The Scottish Medicines Consortium has approved NHS funding for treatments for blood cancer and a rare muscle disorder.

Previous page 1 2 3 4 Next page